View Older Stories

Feb 26, 2026 07:14AM Kymera Therapeutics (KYMR) Misses Q4 EPS by 18c

Feb 25, 2026 04:10PM Piper Sandler Assumes Kymera Therapeutics (KYMR) at Overweight

Jan 29, 2026 07:02AM Kymera begins dosing first patient in phase 2b asthma trial

Jan 13, 2026 07:01AM Kymera Therapeutics outlines 2026 clinical trial plans

Jan 6, 2026 05:35AM Wolfe Research Downgrades Kymera Therapeutics (KYMR) to Peerperform

Dec 16, 2025 05:15AM Kymera Therapeutics (KYMR) PT Raised to $103 at RBC Capital

Dec 11, 2025 07:33AM Kymera Therapeutics (KYMR) PT Raised to $110 at Stephens

Dec 11, 2025 04:43AM Kymera Therapeutics (KYMR) PT Raised to $120 at Mizuho

Dec 10, 2025 08:25AM Kymera Therapeutics (KYMR) PT Raised to $134 at H.C. Wainwright

Dec 9, 2025 02:27PM Kymera Therapeutics (KYMR) PT Raised to $122 at Jefferies

Dec 9, 2025 08:46AM Kymera Therapeutics (KYMR) PT Raised at Piper Sandler Following Positive BroADen Data

Dec 9, 2025 06:10AM Kymera Therapeutics (KYMR) PT Raised to $120 at Oppenheimer

Dec 9, 2025 05:33AM Kymera Therapeutics (KYMR) PT Raised to $116 at Wells Fargo

Dec 8, 2025 04:07PM Kymera Therapeutics (KYMR) PT Raised to $118 at Leerink Partners

Dec 8, 2025 04:01PM Kymera Therapeutics (KYMR) PT Raised to $127 at Morgan Stanley

Dec 8, 2025 04:00PM Kymera Therapeutics (KYMR) PT Raised to $138 at BTIG

Dec 8, 2025 09:56AM Kymera Therapeutics (KYMR) PT Raised to $114 at Stifel

Dec 8, 2025 06:59AM Kymera Therapeutics (KYMR) Halted, News Pending

Nov 26, 2025 08:55AM Kymera Therapeutics (KYMR) PT Raised to $80 at Truist Securities

Nov 25, 2025 07:01AM Kymera Therapeutics starts phase 2b atopic dermatitis trial

Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers

Nov 14, 2025 08:08AM Kymera Therapeutics' (KYMR) Ph2b AD Solidifying First-in-Class Position - Stifel

Nov 5, 2025 06:17AM Kymera Therapeutics (KYMR) PT Raised to $84 at H.C. Wainwright

Nov 4, 2025 01:19PM Kymera Therapeutics (KYMR) PT Raised to $67 at Oppenheimer

Nov 4, 2025 07:04AM Kymera Therapeutics (KYMR) Misses Q3 EPS by 18c

Nov 3, 2025 02:33AM Guggenheim Assumes Kymera Therapeutics (KYMR) at Buy

Oct 27, 2025 07:00AM Kymera presents preclinical data for oral IRF5 degrader KT-579

Oct 24, 2025 05:27AM Citi Adds Kymera Therapeutics (KYMR) to 90-Day Upside Catalyst Watch

Oct 20, 2025 04:03PM Mizuho Starts Kymera Therapeutics (KYMR) at Outperform

Oct 7, 2025 09:01AM Stifel Reiterates Buy Rating on Kymera Therapeutics (KYMR)

Sep 30, 2025 04:29PM Kymera Therapeutics (KYMR) PT Raised to $63 at Oppenheimer

Sep 30, 2025 08:08AM Kymera Therapeutics (KYMR) PT Raised to $68 at Truist Securities

Sep 19, 2025 06:48AM Kymera Therapeutics (KYMR) PT Raised to $70 at H.C. Wainwright

Sep 17, 2025 04:35AM Barclays Starts Kymera Therapeutics (KYMR) at Overweight

Sep 16, 2025 02:30AM RBC Capital Starts Kymera Therapeutics (KYMR) at Outperform

Sep 11, 2025 05:39AM Kymera Therapeutics (KYMR) PT Raised to $88 at Wolfe Research

Aug 11, 2025 07:04AM Kymera Therapeutics (KYMR) Misses Q2 EPS by 12c

Jul 7, 2025 08:09AM Kymera Therapeutics (KYMR) PT Lowered to $65 at Brookline Capital Markets

Jul 3, 2025 04:25AM Morgan Stanley Assumes Kymera Therapeutics (KYMR) at Overweight

Jun 27, 2025 12:19PM Stifel Defending Kymera Therapeutics (KYMR): 'We see any weakness from today's news as a buying opportunity'

Jun 27, 2025 09:37AM Kymera Therapeutics (KYMR) PT Raised to $54 at BofA Securities

Jun 26, 2025 07:36AM Kymera Therapeutics (KYMR) PT Raised to $60 at H.C. Wainwright

Jun 25, 2025 04:06PM Kymera Therapeutics (KYMR) announces $250 million public offering

Jun 25, 2025 04:05PM Kymera Therapeutics (KYMR) PT Lowered to $70 at Brookline Capital Markets

Jun 25, 2025 12:43PM Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies

Jun 25, 2025 10:32AM Stifel says buy Kymera Therapeutics (KYMR) on today's weakness

Jun 25, 2025 09:21AM Leerink Partners Reiterates Outperform Rating on Kymera Therapeutics (KYMR)

Jun 25, 2025 07:05AM Kymera Therapeutics (KYMR) Announces Sanofi IRAK4 Collaboration Update

Jun 25, 2025 07:02AM Gilead Sciences (GILD) and Kymera Therapeutics (KYMR) Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Jun 3, 2025 09:07AM UBS Reiterates Buy Rating on Kymera Therapeutics (KYMR)

View Older Stories